1 recruiting, 1 terminated, 1 unknown. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Recruiting 1, Terminated 1, Unknown 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow Prostatic Disease: new trials by email Literature Review of Prostatic Disease trials Research Report on Prostatic Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer Gedatolisib, Darolutamide - mCRPC (Metastatic Castration-resistant Prostate Cancer), Genital Diseases, Male | Phase 1 / Phase 2 | Recruiting | Celcuity Inc | 54 | 2024-01-01 | 2026-04-13 |
| EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC 177Lu-PSMA-617, Ipilimumab, Nivolumab - Prostatic Neoplasms, Genital Neoplasms, Male | Phase 2 | Unknown | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | 93 | 2022-04-29 | 2023-12-15 |
| High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy 18F-PSMA - Prostatic Neoplasms, Genital Neoplasms, Male | Phase 2 | Terminated | Alessandro D'Agnolo | 62 | 2021-04-06 | 2026-07-22 |
Prostatic Diseases (3) · Prostatic Neoplasms (3) · Genital Diseases, Male (2) · Genital Neoplasms, Male (2) · Neoplasms (2) · Neoplasms by Site (2) · Urogenital Neoplasms (2) · Male Urogenital Diseases (1) · Prostatic Neoplasms, Castration-Resistant (1)
Genital Diseases (3) · Urogenital Diseases (3) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Male Urogenital Diseases (2) · Genital Diseases, Male (1) · Genital Neoplasms, Male (1) · Neoplasms (1) · Neoplasms by Site (1) · Urogenital Neoplasms (1)
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid (1) · Ipilimumab (1) · Nivolumab (1) · Pluvicto (1) · darolutamide (1) · gedatolisib (1)
Alessandro D'Agnolo (1) · Australian and New Zealand Urogenital and Prostate Cancer Trials Group (1) · Celcuity Inc (1)
United States (2) · Australia (1) · France (1) · Spain (1) · United Kingdom (1)
Alessandro D'Agnolo, MD (1) · Nadene Zack, MS (1) · Shahneen Sandhu, MBBS, FRACP (1)